5th Mar 2019 11:35
LONDON (Alliance News) - Clinical stage drug developer Evgen Pharma PLC on Tuesday said a study has been published showing that its lead product, SFX-01, reduces residual disability in a model of relapsing-remitting multiple sclerosis.
Shares in Evgen were up 6.6% at 16.52 pence on Tuesday.
Relapsing-remitting MS is the most common form of the disease and is when patients experience attacks of symptoms that come and go, rather than remaining constant. Common MS symptoms include pain, fatigue, and difficulties with vision.
The study was published in the journal Multiple Sclerosis & Related Disorders and tested the efficacy of SFX-01 in mice with a model of the MS condition. Data from the study showed that SFX-01 reduced residual disability, reducing the severity of relapses and improving recovery during follow-up.
Evgen Chief Executive Steve Franklin said: "The leading product in MS treatment generates revenues of several billion dollars per annum despite an adverse side effect profile. There is an attractive opportunity for oral disease-modifying agents with comparable or better efficacy and an improved side-effect profile."
Looking ahead, SFX-01 is also being assessed as a treatment for other forms of MS, such as secondary progressive MS, where patients who used to have the relapsing-remitting form of the stop having remission periods and instead find their symptoms getting worse.
Related Shares:
EVG.L